These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38369808)

  • 1. Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma.
    Pu LF; Li MM; Feng XJ; Zhang T; Hu LH; Zheng HM; Charwudzi A; Ding YY; Liu J; Liu ZL; Xiong SD
    J Leukoc Biol; 2024 May; 115(6):1094-1107. PubMed ID: 38369808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
    Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
    Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy.
    Foureau DM; Guo F; Steuerwald NM; Druhan LJ; Avalos BR; Copelan E; Sun D; Hu B; Moyo T; Jacobs R; Park S; Ghosh N
    Exp Hematol; 2024 Jan; 129():104125. PubMed ID: 38743005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin's lymphoma patients.
    Wang Y; Wang J; Zhu F; Wang H; Yi L; Huang K; Zhai Z
    Immun Inflamm Dis; 2022 May; 10(5):e616. PubMed ID: 35478441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 8. Expansion and activation of monocytic-myeloid-derived suppressor cell via STAT3/arginase-I signaling in patients with ankylosing spondylitis.
    Liu YF; Zhuang KH; Chen B; Li PW; Zhou X; Jiang H; Zhong LM; Liu FB
    Arthritis Res Ther; 2018 Aug; 20(1):168. PubMed ID: 30075733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
    Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
    Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.
    Barrera L; Montes-Servín E; Hernandez-Martinez JM; Orozco-Morales M; Montes-Servín E; Michel-Tello D; Morales-Flores RA; Flores-Estrada D; Arrieta O
    Cancer Immunol Immunother; 2018 Sep; 67(9):1393-1406. PubMed ID: 29974189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.
    Sato Y; Shimizu K; Shinga J; Hidaka M; Kawano F; Kakimi K; Yamasaki S; Asakura M; Fujii SI
    Oncoimmunology; 2015 Mar; 4(3):e995541. PubMed ID: 25949922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
    Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
    Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Ferrer G; Jung B; Chiu PY; Aslam R; Palacios F; Mazzarello AN; Vergani S; Bagnara D; Chen SS; Yancopoulos S; Xochelli A; Yan XJ; Burger JA; Barrientos JC; Kolitz JE; Allen SL; Stamatopoulos K; Rai KR; Sherry B; Chiorazzi N
    Leukemia; 2021 Nov; 35(11):3163-3175. PubMed ID: 33935280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginase 1
    Neri D; Carevic-Neri M; Brück J; Holstein J; Schäfer I; Solimani F; Handgretinger R; Hartl D; Ghoreschi K
    Exp Dermatol; 2021 Jun; 30(6):782-791. PubMed ID: 33528891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients.
    Okano S; Abu-Elmagd K; Kish DD; Keslar K; Baldwin WM; Fairchild RL; Fujiki M; Khanna A; Osman M; Costa G; Fung J; Miller C; Kayashima H; Hashimoto K
    Am J Transplant; 2018 Oct; 18(10):2544-2558. PubMed ID: 29509288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.
    Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF
    Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
    Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
    Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
    Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
    Front Immunol; 2019; 10():691. PubMed ID: 31001284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
    Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
    Front Immunol; 2020; 11():1299. PubMed ID: 32719675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.